Cwm LLC Sells 538 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Cwm LLC trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 1.2% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 43,400 shares of the biopharmaceutical company’s stock after selling 538 shares during the period. Cwm LLC’s holdings in Alnylam Pharmaceuticals were worth $8,307,000 as of its most recent filing with the SEC.

Several other institutional investors have also made changes to their positions in the business. Quent Capital LLC boosted its holdings in Alnylam Pharmaceuticals by 246.0% during the fourth quarter. Quent Capital LLC now owns 173 shares of the biopharmaceutical company’s stock valued at $33,000 after purchasing an additional 123 shares in the last quarter. Anchor Investment Management LLC acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter valued at $38,000. Lindbrook Capital LLC grew its position in Alnylam Pharmaceuticals by 37.2% in the fourth quarter. Lindbrook Capital LLC now owns 369 shares of the biopharmaceutical company’s stock valued at $71,000 after acquiring an additional 100 shares during the period. Acadian Asset Management LLC raised its stake in Alnylam Pharmaceuticals by 52.4% during the third quarter. Acadian Asset Management LLC now owns 904 shares of the biopharmaceutical company’s stock worth $160,000 after acquiring an additional 311 shares in the last quarter. Finally, Avitas Wealth Management LLC bought a new position in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $204,000. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on ALNY shares. Wells Fargo & Company dropped their target price on shares of Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating for the company in a research report on Friday, February 16th. HC Wainwright reiterated a “buy” rating and issued a $395.00 target price on shares of Alnylam Pharmaceuticals in a research note on Tuesday, March 5th. Wolfe Research began coverage on Alnylam Pharmaceuticals in a report on Thursday, February 15th. They issued a “peer perform” rating on the stock. William Blair reaffirmed an “outperform” rating on shares of Alnylam Pharmaceuticals in a report on Monday, April 8th. Finally, Royal Bank of Canada reissued an “outperform” rating and issued a $235.00 price objective on shares of Alnylam Pharmaceuticals in a research note on Tuesday, February 20th. Nine equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $216.12.

Alnylam Pharmaceuticals Price Performance

Shares of NASDAQ ALNY opened at $145.79 on Tuesday. The company’s 50 day simple moving average is $151.09 and its 200 day simple moving average is $166.50. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $143.50 and a fifty-two week high of $218.88. The firm has a market capitalization of $18.36 billion, a P/E ratio of -40.95 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Thursday, February 15th. The biopharmaceutical company reported ($1.10) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.20) by $0.10. The company had revenue of $439.72 million during the quarter, compared to analyst estimates of $439.38 million. The business’s revenue for the quarter was up 31.2% compared to the same quarter last year. During the same period last year, the company earned ($1.68) EPS. Sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -4.54 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.